Haisco Pharmaceutical Group

002653.SZPhase 3

Chengdu, ChinaFounded 1993haisco.com

Haisco Pharmaceutical Group operates as an integrated pharmaceutical company in China with capabilities spanning drug discovery, development, manufacturing, and commercialization. The company maintains a diversified portfolio of both innovative drugs and generic pharmaceuticals, with particular strength in oncology, cardiovascular, and respiratory therapeutic areas. As a publicly traded company on the Shenzhen Stock Exchange, Haisco has established itself as a significant player in the Chinese pharmaceutical market with ongoing expansion of its R&D capabilities and product pipeline.

Market Cap

$8.3B

Founded

1993

Focus

Biotech

002653.SZ · Stock Price

USD 51.03+33.71 (+194.63%)

Historical price data

AI Company Overview

Technology Platform

Integrated pharmaceutical platform combining drug discovery, development, manufacturing, and commercialization capabilities with focus on both innovative drugs and generic pharmaceuticals.

Pipeline Snapshot

128

128 drugs in pipeline, 23 in Phase 3

Drug	Indication	Stage
Ciprofol + Propofol	Anesthesia, General	Approved
Cyclopofol + Propofol	Postoperative Delirium	Approved
Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate i...	Acute Drug Induced Liver Injury	Approved
Crisugabalin + Placebo	Parkinson's Disease With Nociceptive Pain	Approved
Cipepofol	Anesthesia	Approved

Funding History

IPOUndisclosedUndisclosedMar 15, 2012

Opportunities

Haisco is well-positioned to capitalize on China's rapidly growing pharmaceutical market driven by an aging population and expanding healthcare access.

The company's integrated business model provides multiple growth avenues through both innovative drug development and generic pharmaceutical expansion.

Risk Factors

Key risks include regulatory changes in Chinese pharmaceutical policy, intense competitive pressure from both domestic and international players, and clinical development risks associated with innovative drug programs.

Manufacturing compliance and quality standards present ongoing operational challenges.

Competitive Landscape

Haisco operates in a highly competitive Chinese pharmaceutical market with numerous domestic players and increasing international presence. The company differentiates through its integrated business model, therapeutic area focus, and established domestic distribution capabilities.

Publications

Patents

Pipeline

128